Cellectis Drops Blood-Cancer CAR-Ts; Citizens Cuts Rating
Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.
/ 491 items
#XY Event-Driven Stocks↓
Contineum’s J&J-Partnered Depression Drug Misses Phase 2 Goal
Contineum said its J&J-partnered drug PIPE-307 missed the Phase 2 primary goal of improving MADRS scores at Day 5 versus placebo.
GSK posts strong lung cancer data at WCLC as it seeks first-line Jideytro approval
Jideytro shrank tumors in 94% of untreated ROS1 patients; Ris-Rez cut death risk 54% vs topotecan in China. FDA filing planned this year.
FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections
FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.
Definium Reports Third Phase 3 Win for Fast-Dissolve LSD Therapy
Definium’s DT120 ODT LSD tablet cut GAD anxiety scores 5.1 points vs placebo in Phase 3. Effects started by day 2. FDA filing targeted for 2027.
BioNTech Drug Nearly Doubles Survival in Hard-to-Treat Lung Cancer
Updated PRESERVE-003 data: gotistobart showed 18.5 vs 10 months median survival vs chemo in previously treated squamous NSCLC. Pivotal stage ongoing.